MedTrace Logo

Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy

NCT03325036 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-12-04

No results posted yet for this study

Summary

The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Conditions

  • Head and Neck Cancers Patients

Interventions

DIAGNOSTIC_TEST

Serum levels of immunologic profiles

Serum levels of immunologic profiles before and after chemoradiotherapy

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Jenny Ling-Yu Chen, MD · National Taiwan University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03325036 on ClinicalTrials.gov